FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort-Reference-Cited by-同舟云学术

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort

Published:2013-09-17 Issue:1 Volume:32 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Maugeri-Saccà Marcello,Pizzuti Laura,Sergi Domenico,Barba Maddalena,Belli Franca,Fattoruso Silvia Ileana,Giannarelli Diana,Amodio Antonella,Boggia Sara,Vici Patrizia,Di Lauro Luigi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1756-9966-32-67.pdf

Reference30 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.

2. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev. 2013, 39: 60-67. 10.1016/j.ctrv.2012.09.007.

3. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997, 8: 163-168. 10.1023/A:1008243606668.

4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993, 72: 37-41. 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P.

5. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995, 71: 587-591. 10.1038/bjc.1995.114.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer;ESMO Gastrointestinal Oncology;2024-09

2. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study;Current Medical Research and Opinion;2024-06-22

3. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma;JAMA Oncology;2024-06-01

4. Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape;ESMO Gastrointestinal Oncology;2024-06

5. Neoadjuvant polychemotherapy in the complex treatment of gastric cancer;Health and Ecology Issues;2023-07-10